The customary approach to early-phase clinical trial design, where the focus is on identification of the maximum tolerated dose, is not always suitable for noncytotoxic or other targeted therapies.
Sankhyā: The Indian Journal of Statistics, Series B (2008-), Vol. 78, No. 1 (May 2016), pp. 66-77 (12 pages) We consider the problem of unbiased estimation of a finite population mean (or proportion) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results